Macquarie Group LTD Surface Oncology, Inc. Transaction History

Macquarie Group LTD

  • $90.3 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
BUY
$6.87 - $10.48 $2.4 Million - $3.67 Million
350,000 New
350,000 $3.23 Million

Others Institutions Holding SURF

# of Institutions
2
Shares Held
315K
Call Options Held
0
Put Options Held
0
View Full List

About Surface Oncology, Inc.

SURF Quotes by TradingView
  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email